GUFICBIO · Gufic Biosciences Ltd · Biotechnology & Drugs
GUFICBIO · Gufic Biosciences Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
7.1% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹261 Cr
Revenue YoY
PAT YoY
+70.7%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
6.4
P/S (TTM)
4.4
Sector P/E
36.3
Dividend yield
+0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| GUFICBIO (this stock) | 55.6 | 6.4 | +7.5% | +11.1% | 0.61 | +0.0% |
| Sun Pharmaceutical Industries | 38.9 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 76.4 | 20.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
3.43% (-0.20pp)
falling 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: Gufic Biosciences Limited reported Q1 FY27 earnings with revenue of INR260.8 crores, up from INR226.9 crores in Q1 FY26, and EBITDA of INR47.2 crores, up from INR33.2 crores. EBITDA margin improved to 18.09% from 14.6%, while profit before tax rose to INR30.1 crores (11.56% margin) from INR16.3 crores (7.1%). Profit after tax reached INR22.46 crores (8.61% margin) compared to INR12.1 crores (5.3%). The company highlighted operational progress, including Indore plant nearing full capacity utilization (projected 40-45% by year-end), in-house production of depot presentations, and expansion into new therapeutic areas like lipid-based antifungals. Strategic initiatives included a shift to B2C models in international markets, partnerships for GLP-1 CMO operations, and a tie-up with CHAI for liposomal amphotericin B. Management guided toward 15-20% annual revenue growth and discussed plans to optimize product mix for higher margins. Capacity utilization and product diversification are expected to drive future revenue, with peak revenue estimates of INR1,600-2,000 crores achievable without further capex. The company also noted employee additions linked to Indore's expansion and international market strategies.
The document emphasizes operational progress, revenue growth, and strategic initiatives with optimistic outlooks on future capacity and margin improvements.
Sourced from an exchange-filed transcript, dated 21 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Gufic Biosciences Limited provided a written transcript of its earnings conference call held on February 16, 2026. The document was submitted to both the BSE Limited and the National Stock Exchange of India Limited, in compliance with SEBI regulations. The transcript is available on the company's website for public access. The communication was signed by Ami Shah, the Company Secretary and Compliance Officer.
The document presented factual information regarding the earnings conference call and compliance with regulatory requirements.
Sourced from an exchange-filed transcript, dated 20 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation from Gufic Biosciences Limited detailed the company's unaudited financial results for the quarter and nine months ended December 31, 2025. Management reported that the Indore facility, designed for complex injectable manufacturing, commenced production in October 2024 and is on track for global regulatory clearances. The presentation highlighted a focus on expanding hospital coverage in critical care and scaling the women's health platform, particularly in assisted reproductive technology. Financially, total revenue for Q3 FY26 was reported at Rs. 231.1 crore, with an EBITDA of Rs. 37.1 crore. The company emphasized its strategic initiatives in R&D, including advancements in immunotherapy and chronic care products. Gufic also noted its efforts to enhance its international business and CMO services, aiming for a robust growth trajectory.
Management emphasized growth initiatives and operational progress.
Sourced from an exchange-filed presentation, dated 13 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedGufic Biosciences Limited (GUFICBIO) reported FY2021-22 financial highlights with revenue from operations and EBITDA figures, though exact numbers are not specified in the provided text. The company maintained compliance with corporate governance, secretarial standards, and SEBI regulations, with no adverse remarks from auditors or secretarial compliance reports. No applications under the Insolvency and Bankruptcy Code, 2016 were pending, and no defaults in loan repayments or interest payments were noted. The company has implemented policies for director appointments, remuneration, and internal controls, with no material non-compliance or penalties. The auditor's report did not highlight significant financial discrepancies, and the company has no overdue statutory dues. However, the exact financial figures and detailed performance metrics are not provided in the text.
- No defaults in loan repayments or interest payments during FY2021-22.
- No applications under the Insolvency and Bankruptcy Code, 2016 were pending.
- Compliance with corporate governance, secretarial standards, and SEBI regulations confirmed.
- No material non-compliance or penalties noted in the report.
- Internal controls and director policies are in place with no adverse findings.
Key takeaway: Gufic Biosciences Limited maintained compliance with regulatory and corporate governance standards in FY2021-22, with no defaults or pending insolvency cases, though specific financial performance metrics are not detailed in the provided text.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (2 items); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
2 occurrencesRecent (last 12 months)
The company was fined ₹8,000 and ₹1,72,000 by BSE and NSE for non-compliance with Regulation 17(1A) of the SEBI Listing Regulations regarding the appointment of an additional director without shareholder approval. The company remitted the fines and has a pending waiver application for the NSE fine.
Earlier (1-3 years ago)
The company was fined ₹8000 for the quarter ended June 2024 and ₹172,000 for the quarter ended September 2024 for alleged non-compliance of Regulation 17(1A) of the SEBI Listing Regulations regarding the appointment of Mr. Kamal Kishore Seth as an Additional Director without a special resolution.
Default / Covenant Breach
1 occurrenceRecent (last 12 months)
The company has a wilful defaulter issue under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has disputed liabilities on account of Sales Tax, Excise Duty, and Income Tax, and guarantees executed including Letter of Credit and Bank Guarantee as of March 31st, 2026.
Earlier (1-3 years ago)
The company has disputed liabilities on account of Sales Tax, Excise Duty, and Income Tax as of March 31st, 2025 and March 31st, 2024.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company has disclosed transactions with related parties including Gufic Private Limited, Prime Bio Inc, and Veira Life FZE, which are enterprises over which Key Managerial Personnel (KMP) can exercise influential control, as well as purchases from relatives of KMP such as Pooja Pranav Choksi and Rita Ghosh.
Earlier (1-3 years ago)
The company has disclosed transactions with related parties, including services received from Gufic Private Limited, Prime Bio Inc, and Vishoushadhi Products and Services Private Limited, as well as purchases from Gufic Chem Private Limited and payments of rent to Gufic Private Limited and Gufic Chem Private Limited.
Statutory dues in dispute
1 occurrenceEarlier (1-3 years ago)
The company has statutory dues pending under various acts including Income Tax, Central Excise, and Gujarat VAT, with disputes pending at different appellate authorities and commissioner levels.
Management & Board Governance
1 occurrenceRecent (last 12 months)
Several directors and key managerial personnel resigned or ceased their roles in 2024, including Mr. Dilip Ghosh (resigned June 28th, 2024), Mr. Gopal M. Daptari (cessation November 24th, 2024), and others.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
3.74% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).